Monday, August 14, 2023

CAS and Announce a Strategic Collaboration to Accelerate Drug Discovery

COLUMBUS, Ohio & WARSAW, Poland - Friday, 11. August 2023

The two organizations are joining forces to develop pioneering AI-based solutions for efficient chemical synthesis planning to accelerate the development of novel pharmaceuticals.

(BUSINESS WIRE) -- CAS, a division of the American Chemical Society specializing in scientific information solutions, and, a tech-bio leader in AI-based solutions for pharmaceutical chemistry, have established a strategic collaboration focused on the joint development of computer-aided synthesis design technologies to accelerate scientific breakthroughs in early-stage drug discovery and aid chemists in the discovery of novel small molecules.

Leveraging their existing technologies and expertise, including’s proprietary generative deep learning models and synthesis planning platform with chemist-first UI, and CAS’ world-class chemical reactions content collection and deep industry knowledge, the two organizations will work together to enhance and develop solutions for efficient and innovative chemical synthesis planning. Beyond their complementary capabilities, the organizations’ collaboration is fueled by their shared goal to empower scientists and accelerate breakthroughs.

“We are thrilled to bring to market the first generative models for chemistry trained on CAS’ content, as CAS’ strategic partner for synthetic accessibility and retrosynthesis deep learning enhancements,” says Piotr Byrski,’s co-founder and CEO. “Generative AI has demonstrated amazing feats across multiple fields when trained on large datasets and I believe that there’s a clear need for bringing this to drug discovery. I’m very proud of both CAS & teams, who have worked diligently over the past year to identify how we can bring together’s unique technology and expertise in AI and CAS’ comprehensive chemical dataset. I am excited that in the upcoming months and years, we will witness the outcomes of this collaboration and the significant impact it will have on the pharmaceutical industry.”

The first joint offering, M1 RetroScore powered by CAS, will be part of the product suite and will replace their current synthetic accessibility scoring tool, RetroSAS. Leveraging the recent advances in generative model development by’s team, the solution uses machine learning models trained on the CAS best-in-class chemical reactions content to predict the likelihood of synthesis for novel molecules. M1 RetroScore powered by CAS provides all users with synthetic accessibility scores along with the corresponding potential top synthesis pathways for given targets. For users of CAS SciFindern, the tool will connect with reference reactions within the CAS SciFindern platform. M1 RetroScore powered by CAS is the first commercially available synthetic accessibility scoring tool trained on CAS content. and CAS are also collaborating to enhance the world-class retrosynthesis capabilities already available in CAS SciFindern. As part of their continued dedication to improving their solutions, CAS will incorporate’s deep learning models to improve its synthesis predictions and aid scientists in exploring potential synthetic routes for small molecules, thus accelerating scientific breakthroughs.

“Chemical reactions and retrosynthesis capabilities from CAS are unparalleled,” says Tim Wahlberg, Chief Product Officer for CAS. “By collaborating with, we will bring a unique combination of capabilities to the market to solve challenges in synthesis planning – both early-stage screening for synthesizability as well as laboratory and scale-up synthesis design. These solutions will continue to reduce time spent in the discovery process for scientists, empowering them with efficiencies throughout their innovation journey.”

M1 RetroScore powered by CAS will officially launch on August 14 and will be presented at’s booth #364 at ACS Fall 2023 from August 14-16 in San Francisco. Learn more at

About CAS

CAS is a leader in scientific information solutions, partnering with innovators around the world to accelerate scientific breakthroughs. CAS employs over 1,400 experts who curate, connect, and analyze scientific knowledge to reveal unseen connections. For over 100 years, scientists, patent professionals, and business leaders have relied on CAS solutions and expertise to provide the hindsight, insight, and foresight they need so they can build upon the learnings of the past to discover a better future. CAS is a division of the American Chemical Society. Connect with us at

About (M1) is a seed-stage tech-bio company developing cutting-edge AI-enabled chemical synthesis planning solutions to support early-stage drug discovery pipelines. M1’s interdisciplinary team of machine learning experts, software engineers and chemists, collaboratively develops solutions for analysis of synthetic accessibility, chemical reaction prediction, and reaction condition recommendations, leveraging advances in AI and proprietary data from’s own high-throughput laboratory. Their products are designed for chemists, by chemists. brought the first commercially available deep learning retrosynthesis planning solution to market in 2019 and has raised over $5 million USD to date.

Learn more at


View source version on



CAS – Zornitsa Ivanova, mob. +1 312-806-3983, email: – Alicja Górka-Pruszczak, mob. +48 690 194 094, email:

No comments:

Post a Comment